Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120939 · ClinicalTrials.gov registry record · Phase 1
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
A Phase 1 study of Breast Neoplasms and Prostatic Neoplasms, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00120939: Completed Phase 1 study of Breast Neoplasms and Prostatic Neoplasms, sponsored by Pharmacyclics.
NCT00120939 is a Phase 1 study of Breast Neoplasms and Prostatic Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 25 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00120939, a Phase 1 study of Breast Neoplasms and Prostatic Neoplasms, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.
Conditions Studied
Interventions
- DRUG Motexafin Gadolinium
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Phase | Phase 1 |
What the finished NCT00120939 record still lists
NCT00120939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Motexafin Gadolinium is the first listed.
NCT00120939 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00120939 about?
NCT00120939 is a clinical study titled "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer". The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be eval...
What is the current status of trial NCT00120939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants.
What conditions does trial NCT00120939 study?
This clinical trial studies the following conditions: Breast Neoplasms, Prostatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms.
What interventions are being tested in trial NCT00120939?
The interventions under investigation include: Motexafin Gadolinium (DRUG).
Who is sponsoring clinical trial NCT00120939?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00120939 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00120939's enrollment target sits among peer trials
25 90th of 97 higher than 7 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer